BioSpace News Archive

Y-mAbs Therapeutics, Inc. announced the publication of preclinical GD2-SADA data at the 2024 American Society of Clinical Oncology Annual Meeting, taking place May 31 through June 4, 2024, in Chicago, IL.

ClearPoint Neuro, Inc. announces full market release of its SmartFrame OR platform and ClearPoint Prism Neuro Laser Therapy System at the 2024 Biennial Meeting of the American Society of Stereotactic and Functional Neurosurgery from Saturday, June 1st – Tuesday, June 4th in Nashville.

Ankyra Therapeutics, a clinical-stage oncology company developing anchored immunotherapies to improve the therapeutic window for immuno-oncology drugs, announced that it is presenting a Trial in Progress poster for the phase 1 ANCHOR clinical trial at the 2024 American Society of Clinical Oncology Annual Meeting being held May 31 – June 4, 2024 in Chicago, IL.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation, shared new clinical data from its ongoing KT-253 Phase 1 trial.

Immunocore Holdings plc presented three posters about KIMMTRAK® for the treatment of patients with unresectable or metastatic uveal melanoma at the 2024 ASCO Annual Meeting.

Immunocan announces significant progress in the construction of its alpaca-derived nanobody discovery platform, ImmuAlpaca® mouse.

Data demonstrated promising monotherapy activity with olomorasib across a range of KRAS G12C-mutant solid tumors, including non-small cell lung cancer, and a tolerability profile in combination with pembrolizumab that is well-suited to first-line lung cancer development

Boehringer Ingelheim’s new program to cap out-of-pocket costs at $35 per month for eligible patientsi for the company’s inhalers is now available.

Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence -enabled drug discovery, announced data from an ongoing Phase 1 study of AC699 monotherapy in patients with ER-positive / HER2-negative locally advanced or metastatic breast cancer.

Bristol Myers Squibb announced results from the Phase 3 KRYSTAL-12 study evaluating KRAZATI® compared to standard of care chemotherapy in patients with locally advanced or metastatic KRASG12C-mutated non-small cell lung cancer who had previously received platinum-based chemotherapy, concurrently or sequentially with anti-PD-1 therapy.